Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network's MYLUNG Consortium.
Koselke E, Kaspin-Powell LC, Hough S, Howell J, Robert NJ, Neubauer MA, Bullock SA, Walberg JM, Rammage M, Butrynski JE, Hakimian D, Jotte RM, Meshad MW, Ali K, Waterhouse DM, Coleman RL, Evangelist MC. Koselke E, et al. Among authors: waterhouse dm. J Adv Pract Oncol. 2024 Jul 21:1-10. doi: 10.6004/jadpro.2024.15.8.7. Online ahead of print. J Adv Pract Oncol. 2024. PMID: 39802530 Free PMC article.
A call to action to advance patient-focused and decentralized clinical trials.
Harvey RD, Miller TM, Hurley PA, Thota R, Black LJ, Bruinooge SS, Boehmer LM, Fleury ME, Kamboj J, Rizvi MA, Symington BE, Tap WD, Waterhouse DM, Levit LA, Merrill JK, Prindiville SA, Pollastro T, Brewer JR, Byatt LP, Hamroun L, Kim ES, Holland N, Nowakowski GS. Harvey RD, et al. Among authors: waterhouse dm. Cancer. 2024 Apr 15;130(8):1193-1203. doi: 10.1002/cncr.35145. Epub 2024 Jan 9. Cancer. 2024. PMID: 38193828 No abstract available.
Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.
Waterhouse DM, Rothschild S, Dooms C, Mennecier B, Bozorgmehr F, Majem M, van den Heuvel MH, Linardou H, Chul Cho B, Roberts-Thomson R, Tanaka K, Blais N, Schvartsman G, Holmskov Hansen K, Chmielewska I, Forster MD, Giannopoulou C, Stollenwerk B, Obiozor CC, Wang Y, Novello S. Waterhouse DM, et al. Lung Cancer. 2024 Oct;196:107921. doi: 10.1016/j.lungcan.2024.107921. Epub 2024 Aug 6. Lung Cancer. 2024. PMID: 39303400 Free article. Clinical Trial.
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
He K, Berz D, Gadgeel SM, Iams WT, Bruno DS, Blakely CM, Spira AI, Patel MR, Waterhouse DM, Richards DA, Pham A, Jotte R, Hong DS, Garon EB, Traynor A, Olson P, Latven L, Yan X, Shazer R, Leal TA. He K, et al. Among authors: waterhouse dm. J Thorac Oncol. 2023 Jul;18(7):907-921. doi: 10.1016/j.jtho.2023.02.016. Epub 2023 Feb 24. J Thorac Oncol. 2023. PMID: 36842467 Free PMC article. Clinical Trial.
55 results